(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

How Big Is The Hepatitis Drugs Market In 2025?
In recent years, the market size for hepatitis drugs has been expanding steadily, with projections estimating a rise from $20.04 billion in 2024 to $20.78 billion in 2025. This implies a compound annual growth rate (CAGR) of 3.7%. Factors fueling the growth during the historical period include the discovery of antiviral drugs designed to fight hepatitis viruses, advancements in technologies for hepatitis diagnosis, increased awareness of the global impact of hepatitis, the expansion of vaccination programs targeting hepatitis, and the creation of interferon-based therapies for hepatitis.

The market size for hepatitis medication is projected to witness sustained growth in the coming years, reaching the value of $24.21 billion in 2029, with a compound annual growth rate (CAGR) of 3.9%. This growth during the forecast period is partly due to the introduction of innovative direct-acting antiviral drugs, an increase in hepatitis infections, government efforts toward hepatitis prevention and treatment, advancements in personalized medicine for hepatitis, and the expansion of access to hepatitis medications in developing nations. Key trends expected during this period include the shift from interferon-based therapies to those that are interferon-free, the creation of pan-genotypic antiviral medications for hepatitis C, the incorporation of non-invasive diagnostic techniques for assessing liver fibrosis, the exploration of combination therapies for hepatitis B, and an increased emphasis on eliminating viral hepatitis as a public health concern.

Download a free sample of the hepatitis drugs market report:

What Are The Key Driving Factors For The Growth Of The Hepatitis Drugs Market?
The escalation in the prevalence of various forms of hepatitis is considerably fuelling the hepatitis drug market's expansion. The diverse nature of hepatitis requires distinct drugs for treatment, hence amplifying the need for hepatitis medication. For example, in June 2022, the World Health Organization (WHO), a public health institution based in Switzerland, reported that 296 million individuals were suffering from chronic hepatitis B, with about 1.5 million new infection cases recorded yearly. This surge in hepatitis infections will inevitably boost the hepatitis drug requirement and utilization. Therefore, the rise in various forms of hepatitis is anticipated to stimulate the growth of the hepatitis drugs market in the projected period.

Who Are The Key Players In The Hepatitis Drugs Industry?
Major players in the Hepatitis Drugs include:
. Gilead Sciences Inc.
. F. Hoffmann-La Roche Ltd
. GlaxoSmithKline plc
. Johnson & Johnson
. Merck & Co. Inc.
. Abbott Laboratories
. AbbVie Inc.
. Arbutus Biopharma Corporation
. Aspen Pharmacare Holdings Limited
. Aurobindo Pharma Limited

What Are The Upcoming Trends Of Hepatitis Drugs Market In The Globe?
Leading firms in the hepatitis drugs market are placing emphasis on creating medicines with novel formulations to increase treatment effectiveness, heighten patient adherence, mitigate side effects, and respond to the diverse strains of the hepatitis virus. The FDA Fast Track designation is an established process that expedites the progression and assessment of drugs aimed at addressing serious conditions and meeting unfulfilled medical necessities. Such drugs facilitate quicker patient access to new therapies, predominantly for severe or fatal diseases. For example, a UK-based pharmaceutical firm, GSK plc, was granted the FDA Fast Track designation for their drug, bepirovirsen, intended for the treatment of chronic hepatitis B (CHB) in February 2024. This designation is of considerable importance as it seeks to fast-track the development and evaluation procedure for therapies addressing the unmet medical needs in serious ailments.

What Segments Are Covered In The Hepatitis Drugs Market Report?
The hepatitis drugs market covered in this report is segmented –
1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase Or NS5A Inhibitor Combinations, Hepatitis C Protease Or NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents
2) By Route Of Administration: Oral, Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E

Subsegments:
1) By Interferon Alphas: Pegylated Interferon Alpha, Non-Pegylated Interferon Alpha
2) By HIV NRTIs: Zidovudine, Lamivudine, Abacavir, Tenofovir
3) By Nucleotide Polymerase Or NS5A Inhibitor Combinations: Sofosbuvir Or velpatasvir, Sofosbuvir Or ledipasvir
4) By Hepatitis C Protease Or NS5A Inhibitor Combinations: Glecaprevir Or pibrentasvir, Paritaprevir Or ombitasvir Or dasabuvir
5) By NS5A Inhibitors: Daclatasvir, Ledipasvir, Velpatasvir
6) By Nucleotide Polymerase Inhibitors: Sofosbuvir, Dasabuvir
7) By Nucleoside Analogue Antivirals: Adefovir, Entecavir, Lamivudine
8) By Thrombopoiesis Stimulating Agents: Eltrombopag, Romiplostim

View the full hepatitis drugs market report:

Which Region Is Expected To Lead The Hepatitis Drugs Market By 2025?
In 2024, North America dominated the market for hepatitis drugs. It is anticipated that the Asia-Pacific region will deliver the highest growth rate in the forecasted period. The report on the hepatitis drugs market includes assessments of regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Hepatitis Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025
/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025
/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025
/report/gastrointestinal-drug-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn: "

MENAFN21112025003118003196ID1110377360